Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in District of Columbia: - Kaiser Permanente-Capitol Hill Medical Center — Washington D.C., District of Columbia
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…
Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07776691
Sites in District of Columbia: - MedStar Washington Hospital Center ( Site 0026) — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in District of Columbia: - Medstar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
Sponsor: TerSera Therapeutics LLC
NCT ID: NCT07310420
Sites in District of Columbia: - MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in District of Columbia: - Normunity Investigational Site — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…
Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in District of Columbia: - George Washington University Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening …
Sponsor: Georgetown University
NCT ID: NCT05130606
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care …
Sponsor: Georgetown University
NCT ID: NCT06892275
Sites in District of Columbia: - Georgetown University — Washington D.C., District of Columbia